475084-96-9

Basic information

• Product Name: ( 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butylester )
• Synonyms: ( 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butylester );4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]-1-butanol;[4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]butoxy]acetic acid 1,1-dimethylethyl ester;TUQMNTRUQSTQNJ-UHFFFAOYSA-N
• CAS NO: 475084-96-9
• Molecular Formula: C₂₉H₃₇N₃O₃
• Molecular Weight: 475.62238
• EINECS: -0
• Mol File: 475084-96-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 592.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.090±0.06 g/cm3(Predicted)
• PKA: 2.40±0.10(Predicted)
• CAS DataBase Reference: ( 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butylester )(CAS DataBase Reference)
• NIST Chemistry Reference: ( 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butylester )(475084-96-9)
• EPA Substance Registry System: ( 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butylester )(475084-96-9)

Safety Data

• Hazardous Substances Data: 475084-96-9(Hazardous Substances Data)

Usage

Uses

2-{4-[N-(5,6-Diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid tert-butyl ester is an impurity of Selexipag (S253150), an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.

Upstream product

• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 18591-57-6 2,3-Diphenyl-6-hydroxypyrazine 
• 101727-15-5 2-iodo-5,6,-diphenylpyrazine 
• 39099-23-5 N-isopropyl-N-butylamine 
• 243472-70-0 2-bromo-5,6-diphenylpyrazine 
• 18591-57-6 5,6-diphenyl-2-hydroxypyrazine 
• 41270-66-0 2-chloro-5,6-diphenylpyrazine 
• 475086-75-0 4-[N-(5,6-diphenylpyrazine-2-yl)-N-isopropylamino]-1-butanol 
• 5292-43-3 bromoacetic acid tert-butyl ester 

Downstream Products

• 475086-01-2 Selexipag 
• 475086-74-9 1-bromo-4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butane 
• 475085-57-5 MRE-269 

Relevant articles and documents

Preparation method of medical intermediate

The invention provides a preparation method of a medical intermediate 2 - {4 - [(5, 6 - diphenylpyrazine -2 -yl) (propane -2 -yl) amino] butoxy} acetate. The crystallization method uses a mixed solvent composed of a hydrocarbon and an alcohol, the hydroca

POLYMORPHIC FORMS AND AMORPHOUS SOLID DISPERSION OF SELEXIPAG

The present disclosure relates to crystalline forms of selexipag and their processes for preparation. The present disclosure also relates to an amorphous solid dispersion of selexipag and its processes for their preparation as well as premix of crystalline selexipag and their process.

Preparation method for therapeutic drug selexipag for treating pulmonary arterial hypertension of adults

The invention discloses a preparation method for therapeutic drug selexipag for treating pulmonary arterial hypertension of adults. The therapeutic drug selexipag for treating pulmonary arterial hypertension of adults is prepared through 5-step reaction of starting materials 5-chlorine-2 and 3-diphenyl pyrazine. The invention aims to overcome the defect of higher cost of the present method, shorten the preparation process and provide the preparation method for the therapeutic drug selexipag for treating pulmonary arterial hypertension of adults that is mild in reaction, easy in operation and high in chiral purity.